Rituximab in antibody-mediated rejection following kidney transplantation: clinical and pathological outcomes.

ABSTRACT:

Background

Antibody-mediated rejection (AMR) continues to be a significant contributor to graft failure among transplant recipients. The standard therapeutic regimen for AMR typically encompasses glucocorticoids, intravenous immunoglobulin (IVIG), and plasmapheresis, with rituximab selectively incorporated into treatment protocols. This study aimed to retrospectively evaluate graft function, patient and graft survival rates, and biopsy findings in kidney transplant recipients diagnosed with AMR who were treated with rituximab.

Methods

We conducted a retrospective analysis of kidney transplant recipients who were diagnosed with AMR or mixed rejection at the Izmir City Hospital Organ Transplantation Center between January 2009 and December 2024. The patient cohort was stratifi

SUBMITTER: Yilmaz B 

PROVIDER: S-EPMC12573978 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature